Opinion/decision on a Paediatric investigation plan (PIP): Juluca,rilpivirine,dolutegravir, decision type: , therapeutic area: , PIP number: P/0496/2022
Clinical trials in human medicines
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi,Risankizumab, decision type: , therapeutic area: , PIP number: P/0497/2022
Human medicines European public assessment report (EPAR): Xeljanz, tofacitinib, Arthritis, Rheumatoid, Date of authorisation: 22/03/2017, Date of refusal: 25/04/2013, Revision: 28, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Odevixibat, decision type: , therapeutic area: , PIP number: P/0515/2022
Opinion/decision on a Paediatric investigation plan (PIP): Entospletinib, decision type: , therapeutic area: , PIP number: P/0518/2022
Opinion/decision on a Paediatric investigation plan (PIP): Xenleta,Lefamulin, decision type: , therapeutic area: , PIP number: P/0535/2022
Network Portfolio
Biosimilar medicines: Overview
Biosimilars in the EU - Information guide for healthcare professionals